Volume 31, Issue 144 (January & February 2023)                   J Adv Med Biomed Res 2023, 31(144): 46-56 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi Moghaddam Z, Karimkhanilouei S, Asaadi Tehrani G. Association between Polymorphisms of X-ray Repair Cross Complementing 5 and 6 Promoter Genes and the Risk of Metastatic Breast Cancer. J Adv Med Biomed Res 2023; 31 (144) :46-56
URL: http://journal.zums.ac.ir/article-1-6670-en.html
Association between Polymorphisms of X-ray Repair Cross Complementing 5 and 6 Promoter Genes and the Risk of Metastatic Breast Cancer
Zhaleh Karimi Moghaddam1 , Samaneh Karimkhanilouei2 , Golnaz Asaadi Tehrani *3
1- Dept of Radiation Oncology, Vali- e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2- Dept. of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran
3- Dept. of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran , Drgolnazasaadi@gmail.com
Abstract:   (11635 Views)

Background and Objective: Breast cancer is the second leading cause of cancer-related death in women. Better individualized treatment needs novel prognostic predictors. X-ray repair cross complementing XRCC5 and XRCC6 are coding genes of the Ku protein complex (key components of the non-homologous end-joining [NHEJ] pathway), which could serve as prognostic factors in breast cancer. Hence, in this study, the association of XRCC5 (coding the Ku70 subunit) and XRCC6 (coding the Ku80 subunit) single polymorphisms with the risk of metastatic breast cancer was assessed.
Materials and Methods: This study included 30 breast cancer patients and 30 age-matched healthy women. Tetra-Arms polymerase chain reaction (PCR) and high-resolution melt (HRM) real-time PCR were performed to determine XRCC5 (variable number tandem repeat [VNTR] polymorphism, rs6147172) and XRCC6 (rs132793) polymorphisms, respectively. Demographical and clinical tumor status was recorded for all women. Allele frequencies and related genotypes were identified.
Results: Our results indicated that 34% of patients receiving chemotherapy had metastases in other organs, mostly in the lung. The frequencies of 0R/0R, 1R/1R, 2R/2R, and 1R/R genotypes in the XRCC5 gene were 6.6%, 63.3%, 6.6%, and 23.3%, respectively. No significant association was found between XRCC5 and metastatic breast cancer (P = 0.426). In addition, the XRCC5 polymorphism was associated with progesterone (P = 0.068), as well as the time interval between chemotherapy and relapse (P = 0.069). The frequency of AA, GG, and AG genotypes in XRCC6 were 0%, 33.3%, and 66.7%, respectively. The XRCC6 polymorphism was associated with cancer metastasis. There was a significant relationship between age (P = 0.048) and family history (P = 0.020) with cancer incidence. A significant association was observed between the XRCC6 polymorphism with human epithelial receptor 2 (HER2; P = 0.070) and radiotherapy sessions (P = 0.007).
Conclusion: We speculate that the genetic variation of the XRCC6 gene (rs132793 SNP) might be considered as a diagnostic biomarker in breast cancer, but further studies are necessary to confirm the results.

Keywords: Breast cancer, Metastasis, Polymorphism, XRCC5, XRCC6
Full-Text [PDF 496 kb]   (10470 Downloads) |   |   Full-Text (HTML)  (883 Views)  

✅ We speculate that the genetic variation of the XRCC6 gene (rs132793 SNP) might be considered as a diagnostic biomarker in breast cancer, but further studies are necessary to confirm the results.


Type of Study: Original Research Article | Subject: Clinical Medicine
Received: 2021/08/17 | Accepted: 2022/08/20 | Published: 2022/12/12
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. [DOI:10.3322/caac.20006] [PMID]
2. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2009;1788(4):872-91. [DOI:10.1016/j.bbamem.2008.11.005] [PMID]
3. Jiang WG, Sanders AJ, Katoh M, et al.Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol. 2015; 35 Suppl:S244-S275 [DOI:10.1016/j.semcancer.2015.03.008] [PMID]
4. Scully OJ, Bay BH, Yip G, Yu Y. Breast Cancer Metastasis. Cancer Genomics Proteomics . 2012;9(5):311-20.
5. Poste G, Fidler IJ. The pathogenesis of cancer metastasis.Nature. 1980;283(5743):139-46. [DOI:10.1038/283139a0] [PMID]
6. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis.Breast Cancr Res. 2008;10(1):S2. [DOI:10.1186/bcr1988] [PMID] [PMCID]
7. Mego M, Mani SA, Cristofanilli MJNrCo. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol . 2010;7(12):693-701. [DOI:10.1038/nrclinonc.2010.171] [PMID]
8. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.Mol Biol Cell. 2011;22(14):2423-35. [DOI:10.1091/mbc.e11-04-0306] [PMID] [PMCID]
9. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective.Cancer Res. 2010;70(14):5649-69. [DOI:10.1158/0008-5472.CAN-10-1040] [PMID] [PMCID]
10. Paget S. The distribution of secondary growths in cancer of the breast.Cancer Metastasis Rev. 1989;8:98-101.
11. Nicolson GL. Breast cancer metastasis-associated genes: role in tumour progression to the metastatic state. Biochem Soc Sym. 1998;63:231-43.
12. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res . 2013;2(3):130.
13. Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YCJC. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end‐joining pathway genes: a multiple genotype‐phenotype study.Cancer. 2009;115(13):2939-48. [DOI:10.1002/cncr.24327] [PMID]
14. Dombernowsky SL, Weischer M, Freiberg JJ, et al. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18(8):2339-42. [DOI:10.1158/1055-9965.EPI-09-0447] [PMID]
15. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genet. 2001;27(3):247-54. [DOI:10.1038/85798] [PMID]
16. Evdokimova V, Gandhi M, Rayapureddi J, Stringer JR, Nikiforov YEJE-rc. Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases. Endocr Relat Cancer. 2012; 19(3): 271-81 2012;19(3):271. [DOI:10.1530/ERC-11-0314] [PMID] [PMCID]
17. Siegel R, Ma J, Zou Z, Jemal AJCacjfc. Cancer statistics. CA Cancer J Clin 2014. 2014;64(1):9-29. [DOI:10.3322/caac.21208] [PMID]
18. Li R, Yang Y, An Y, et al. Genetic polymorphisms in DNA double-strand break repair genes XRCC5 , XRCC6 and susceptibility to hepatocellular carcinoma. Carcinogen. 2011;32(4):530-6. [DOI:10.1093/carcin/bgr018] [PMID]
19. Datkhile KD, Patil MN, Durgawale PP, Korabu KS, Joshi SA, Kakade SV. Association of genetic polymorphisms in XRCC4, XRCC5, XRCC6 and XRCC7 in cervical cancer susceptibility from rural population: a hospital based case-control study. Int J. 2018;6(7):2453. [DOI:10.18203/2320-6012.ijrms20182835]
20. Singh A, Singh N, Behera D, Sharma S. Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy. Molec Biol Rep. 2018;45(3):253-61. [DOI:10.1007/s11033-018-4158-z] [PMID]
21. Patil MN, Datkhile KD, Bhosale SJ, et al. Role of genetic polymorphisms in XRCC4, XRCC5, XRCC6 and XRCC7 in breast cancer susceptibility in rural Indian population: a hospital based case-control study from Maharashtra. Int J Health Sci Res. 2016;6(11):24-32. [DOI:10.18203/2320-6012.ijrms20182835]
22. Lee KM, Choi JY, Kang C, et al. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res. 2005;11(12):4620-6. [DOI:10.1158/1078-0432.CCR-04-2534] [PMID]
23. Fu YP, Yu JC, Cheng TC, et al. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 2003;63(10):2440-6.
24. Abdelbaqi K, Di Paola D, Rampakakis E, Zannis-Hadjopoulos M. Ku protein levels, localization and association to replication origins in different stages of breast tumor progression. J Cancer. 2013;4(5):358-70. [DOI:10.7150/jca.6289] [PMID] [PMCID]
25. Cui J, Luo J, Kim YC, et al. Differences of variable number tandem repeats in XRCC5 promoter are associated with increased or decreased risk of breast cancer in BRCA gene mutation carriers. Front Oncol. 2016;6(92). [DOI:10.3389/fonc.2016.00092] [PMID] [PMCID]
26. AL-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RHJO, Therapy. Genetic association of XRCC5 gene polymorphisms with breast cancer among Jordanian women Onco Targets Ther. 2019;12:7923-8. [DOI:10.2147/OTT.S220226] [PMID] [PMCID]
27. Hayden PJ, Tewari P, Morris DW, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Human Molec Genet. 2007;16(24):3117-27. [DOI:10.1093/hmg/ddm273] [PMID]
28. Jia J, Ren J, Yan D, Xiao L, Sun R. Association between the XRCC6 polymorphisms and cancer risks: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(1):e283-e. [DOI:10.1097/MD.0000000000000283] [PMID] [PMCID]
29. Li R, Yang Y, An Y, et al. Genetic polymorphisms in DNA double-strand break repair genes XRCC5, XRCC6 and susceptibility to hepatocellular carcinoma. Carcinogen. 2011;32(4):530-6. [DOI:10.1093/carcin/bgr018] [PMID]
30. Henríquez-Hernández LA, Valenciano A, Foro-Arnalot P, et al. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. Prostate Cancer Prostatic Dis. 2016;19(1):28-34. [DOI:10.1038/pcan.2015.63] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb